Investigation of anticancer mechanism of thiadiazole-based compound in human non-small cell lung cancer A549 cells

Biochemical Pharmacology

Volumn 66, Issue 1, 2003, Pages 115-124

  Chou, Jui Yi ^a   Lai, Shin Yu ^a   Pan, Shiow Lin ^a   Jow, Guey Mei ^b   Chern, Ji Wang ^a   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Bax; Bcl XL; Phosphoinositide 3 kinase; Thiadiazole

Indexed keywords

2,5 BIS[4 (3 DIMETHYLAMINOPROPOXY)STYRYL] 1,3,4 THIADIAZOLE; CASPASE 3; DNA NUCLEOTIDYLEXOTRANSFERASE; GO 13; LACTATE DEHYDROGENASE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CYTOTOXICITY; DOWN REGULATION; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NICK END LABELING; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 0038005576     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00254-5     Document Type: Article

References (33)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
2. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., Barneto I., Lomas M., Garcia M., Lianes P., Montalar J., Vadell C., Gonzalez-Larriba J.L., Nguyen B., Artal A., Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic nonsmall-cell lung cancer. J. Clin. Oncol. 17:1999;12-18.
3. ten Bokkel Huinink W.W., Bergman B., Chemaissani A., Dornoff W., Drings P., Kellokumpu-Lehtinen P.L., Liippo K., Mattson K., von Pawel J., Ricci S., Sederholm C., Stahel R.A., Wagenius G., Walree N.V., Manegold C. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 26:1999;85-94.
4. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., Mattson K., Manegold C., Palmer M.C., Gregor A., Nguyen B., Niyikiza C., Einhorn L.H. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 18:2000;122-130.
5. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., Jiroutek M., Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18:2000;623-631.
6. Kausch I., Bohle A. Antisense oligonucleotide therapy in urology. J. Urol. 168:2002;239-247.
7. Pienta K.J. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin. Oncol. 28(Suppl. 15):2001;3-7.
8. McDonnell T.J., Beham A., Sarkiss M., Andersen M.M., Lo P. Importance of the Bcl-2 family in cell death regulation. Experientia. 52:1996;1008-1017.
9. L and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation. Biochem. Cell Biol. 75:1997;301-314.
10. Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., De Placido S., Basolo F., Angeletti C.A., Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl. Cancer Inst. 89:1997;881-886.
11. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 340:1992;145-146.
12. Kawaguchi T., Yamamoto S., Kudoh S., Goto K., Wakasa K., Sakurai M. Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma. Anticancer Res. 17:1997;3743-3746.
13. Guh J.-H., Chueh S.C., Hwang T.L., Chen J., Teng C.M. Cell proliferation in human prostatic smooth muscle cells involves the modulation of protein kinase C isozymes. Eur. J. Pharmacol. 359:1998;281-284.
14. Bronckers A.L., Goei S.W., Dumont E., Lyaruu D.M., Woltgens J.H., van Heerde W.L., Reutelingsperger C.P., van den Eijnde S.M. In situ detection of apoptosis in dental and periodontal tissues of the adult mouse using annexin-V-biotin. Histochem. Cell Biol. 113:2000;293-301.
15. Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKT ion blocks apoptosis. Cell. 88:1997;435-437.
16. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes. Dev. 13:1999;2905-2927.
17. Zhou H., Li X.M., Meinkoth J., Pittman R.N. Akt regulates cell survival and apoptosis at a postmitochondrial level. J. Cell Biol. 151:2000;483-494.
18. Springer J.E., Nottingham S.A., McEwen M.L., Azbill R.D., Jin Y. Caspase-3 apoptotic signaling following injury to the central nervous system. Clin. Chem. Lab. Med. 39:2001;299-307.
19. Grutter M.G. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J. Cell Sci. 113:2000;753-757.
20. Rosse T., Olivier R., Monney L., Rager M., Conus S., Fellay I., Jansen B., Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 391:1998;496-499.
21. Amos C.L., Woetmann A., Nielsen M., Geisler C., Odum N., Brown B.L., Dobson P.R. The role of caspase 3 and BclxL in the action of interleukin 7 (IL-7): a survival factor in activated human T cells. Cytokine. 10:1998;662-668.
22. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
23. Orlowski R.Z., Baldwin A.S. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 8:2002;385-389.
24. Rosell R., Green M., Gumerlock P. Advances in the treatment of non-small cell lung cancer: molecular markers take the stage. Semin. Oncol. 28(1 Suppl 2):2001;28-34.
25. Gadad A.K., Karki S.S., Rajurkar V.G., Bhongade B.A. Synthesis and biological evaluation of 5-formyl-6-arylimidazo(2,1-b)-1,3,4-thiadiazole-2-N-(dimethyl-aminomethino) sulfonamides as antitumor agents. Arzneimittelforschung. 49:1999;858-863.
26. Asumendi A., Morales M.C., Alvarez A., Arechaga J., Perez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Br. J. Cancer. 86:2002;1951-1956.
27. Kovacic P., Osuna J.A. Jr. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr. Pharm. Des. 6:2000;277-309.
28. Swannie H.C., Kaye S.B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4:2002;37-46.
29. Han J., Richter B., Li Z., Kravchenko V., Ulevitch R.J. Molecular cloning of human p38 MAP kinase. Biochim. Biophys. Acta. 1265:1995;224-227.
30. Obata T., Brown G.E., Yaffe M.B. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit. Care Med. 28(4 Suppl):2000;N67-N77.
31. L in peroxide-resistant A549 and U87MG cells. Toxicol. Sci. 42:1998;109-116.
32. Yamaguchi H., Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 20:2001;7779-7786.
33. Bongartz J.P., Stokbroekx R., Van der Aa M., Luyckx M., Willems M., Ceusters M., Meerpoel L., Smets G., Jansen T., Wouters W., Bowden C., Valletta L., Herb M., Tominovich R., Tuman R. Synthesis and anti-angiogenic activity of 6-(1,2,4-thiadiazol-5-yl)-3-amino pyridazine derivatives. Bioorg. Med. Chem. Lett. 12:2002;589-591.